文献速递临床生化临床免疫

Cobas i601全自动LC-MS/MS系统检测类固醇激素与维生素D的初步分析评估

Preliminary analytical evaluation of the fully automated Cobas i601 LC-MS/MS system for steroid hormones and vitamin D in a clinical laboratory.
PubMed 文献 · Clin Chim Acta · 2026-08-31

本研究在临床实验室对Cobas i601全自动LC-MS/MS系统检测雌二醇、睾酮、醛固酮、雄烯二酮、25(OH)D和24,25(OH)2D进行初步分析评估。按CLSI EP10-A3评估不精密度、偏倚和线性,并与常规免疫分析法比较。所有项目分析性能可接受,但雄烯二酮、雌二醇、醛固酮和25(OH)D与免疫法存在明显系统偏倚。

要点

  • Cobas i601检测六个项目的不精密度和偏倚均满足预设分析性能规范。
  • 睾酮在临床决定水平偏倚可接受,低浓度变异较大。
  • 雄烯二酮、雌二醇、醛固酮和25(OH)D与免疫法存在显著系统偏倚。

核心结论

  • Cobas i601在本初步评估中分析性能可接受,但多个项目与免疫法存在系统差异,需进一步分析和临床验证。

研究设计与样本

  • 按CLSI EP10-A3使用三个水平商业质控品评估不精密度、偏倚和线性,并按CLSI EP09-A3用血清样本与常规免疫法比较。

主要发现

  • 所有项目最大变异系数3.4%,最大偏倚7.8%,均满足预设分析性能规范。
  • 线性在测试范围内确认(p > 0.05)。
  • 睾酮在临床决定水平偏倚1.7%至9.3%可接受,但低浓度变异较大。
  • 雄烯二酮、雌二醇、醛固酮和25(OH)D在中间临床决定水平与免疫法相比系统偏倚分别为20%、-36.5%、-28.5%和-16%。

关键数值与推荐

  • 不精密度和偏倚按CLSI EP10-A3评估,方法比较按CLSI EP09-A3进行。
  • 分析性能规范基于生物学变异设定。
  • 线性确认标准为p > 0.05。

临床怎么用

  • 使用该平台检测雄烯二酮、雌二醇、醛固酮和25(OH)D时,应关注与免疫法的系统偏倚并加强临床沟通。
  • 睾酮低浓度结果需注意变异较大。

局限性

  • 本研究为初步分析评估,需进一步分析和临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Fully automated liquid chromatography-tandem mass spectrometry (LC-MS/MS) platforms aim to combine the analytical specificity and sensitivity of mass spectrometry with the workflow efficiency of automated routine analyzers. This study performed a preliminary analytical evaluation of the Cobas i601 LC-MS/MS system for estradiol, testosterone, aldosterone, androstenedione, 25-hydroxyvitamin D (25(OH)D) and 24,25-dihydroxyvitamin D (24,25(OH)2D), including method comparison with routine immunoassays in a real-world clinical laboratory setting. METHODS: Imprecision, bias, and linearity were assessed according to Clinical and Laboratory Standards Institute (CLSI) EP10-A3 using three levels of commercial quality control material. Results were compared to analytical performance specifications (APS) based on biological variation. Method comparison and bias estimation with routine immunoassays were performed following CLSI EP09-A3 using serum samples. Predicted biases at clinical decision levels (CDL) were evaluated against allowable limits. RESULTS: All assays demonstrated acceptable analytical performance (maximum coefficient of variation 3.4%; maximum bias 7.8%) and fulfilled predefined APS. Linearity was confirmed across the tested ranges (p > 0.05). Testosterone showed acceptable biases at CDL (1.7% to 9.3%) according to the predefined APS, although greater variability was observed at lower concentrations. In contrast, androstenedione, estradiol, aldosterone and 25(OH)D exhibited substantial systematic bias compared with immunoassays (20%, -36.5%, -28.5% and - 16% respectively at intermediate CDL). CONCLUSIONS: The Cobas i601 demonstrated acceptable analytical performance in this first preliminary evaluation. However, systematic differences relative to immunoassays for several analytes highlight the need for close clinician-laboratory communication when implementing this new automated LC-MS/MS platform, and underscore the need for further analytical and clinical validation.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. Serres-Gómez M, González-Casaus ML, Serrano Olmedo MG, et al. Preliminary analytical evaluation of the fully automated Cobas i601 LC-MS/MS system for steroid hormones and vitamin D in a clinical laboratory. Clin Chim Acta. 2026. PMID: 42674091. doi:10.1016/j.cca.2026.121312

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。